ARTICLE | Company News
Forest, Glenmark in asthma, COPD deal
September 23, 2004 7:00 AM UTC
FRX received North American development and commercialization rights to Glenmark's GRC 3886 to treat asthma and chronic obstructive pulmonary disease (COPD). The inhibitor of phosphodiesterase-4 (PDE-...